argenx SE (STU:1AE)
€ 553.6 6 (1.1%) Market Cap: 33.43 Bil Enterprise Value: 30.56 Bil PE Ratio: 0 PB Ratio: 8.44 GF Score: 82/100

argenx SE at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 04:55PM GMT
Release Date Price: €484.1 (+0.25%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Sorry, we're a couple of minutes late, but we'll make up for on the back end. Thanks for joining us, everyone. This is the fireside chat with argenx. My name is Vikram Purohit, I'm one of the biotech analysts with the research team here. I'm joined by my colleague, James Quigley from the EU biopharma team.

Before we get started, I just need to read a brief disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.

With that, very happy to have with us Tim and Karl from argenx. Thank you so much for joining us. Really appreciate your time.

Timothy Van Hauwermeiren;Vikram Purohit
argenx SE - CEO & Executive Director;Morgan Stanley, Research

Thank you for having us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot